Chapter 24
Preventing Recurrence of Hepatocellular Carcinoma after Curative Resection
Stefan Breitenstein MD,
Dimitris Dimitroulis MD,
Beat Müllhaupt,
Stefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorDimitris Dimitroulis MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorBeat Müllhaupt
Department of Gastroenterology and Hepatology, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD,
Dimitris Dimitroulis MD,
Beat Müllhaupt,
Stefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorDimitris Dimitroulis MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorBeat Müllhaupt
Department of Gastroenterology and Hepatology, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Introduction
-
Interferon
-
Iodine-131-l abelled lipiodol
-
Retinoids
-
Other potential approaches for secondary prevention
-
Conclusion
-
Self-assessment questions
-
References
-
Self-assessment answers
References
- Stroffolini T, Andreone P, Andriulli A, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol 1998; 29: 944 – 52.
- Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2000; 35: 421 – 30.
- Fracanzani AL, Conte D, Fraquelli M, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001; 33: 647 – 51.
- Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008; 48 (Suppl 1): S20 – 37.
- Bruix J, Sherman M, Practice Guidelines Committee, AASLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208 – 36.
- Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321 – 8.
- Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005; 242: 36 – 42.
- Bolondi L, Sofi a S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251 – 9.
- Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434 – 40.
- Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330 – 5.
- Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma Gastroenterology 1995; 108: 768 – 75.
- Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145 – 51.
- Bronowicki JP, Boudjema K, Chone L, et al. Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 1996; 24: 293 – 300.
- Markovic S, Gadzijev E, Stabuc B, et al. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. J Hepatol 1998; 29: 650 – 9.
- Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994; 106: 1618 – 24.
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907 – 17.
- Colombo M, Donato MF. Prevention of hepatocellular carcinoma. Semin Liver Dis 2005; 25: 155 – 61.
- Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 1998; 58: 808 – 14.
- von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437 – 48.
- Breitenstein S, Dimitroulis D, Petrowsky H, et al. Interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis – a systemic review and meta-analysis. Br J Surg 2009; 96: 975 – 81.
- Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458 – 65.
- Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831 – 42.
- Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44(6): 1543 – 1554.
- Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228 – 32.
- Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54 – 8.
- Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418 – 22.
- Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299 – 306.
- Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994; 35: 1313 – 18.
- Maini CL, Scelsa MG, Fiumara C, et al. Superselective intraarterial radiometabolic therapy with I-131 lipiodol in hepatocellular carcinoma. Clin Nucl Med 1996; 21: 221 – 6.
- Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997; 26: 1156 – 61.
- Yoo HS, Park CH, Lee JT, et al. Small hepatocellular carcinoma: high dose internal radiation therapy with superselective intraarterial injection of I-131-labeled Lipiodol. Cancer Chemother Pharmacol 1994; 33 (Suppl): S128 – S 133.
- Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999; 353(9155): 797 – 801.
- Partensky C, Sassolas G, Henry L, Paliard P, GJ M. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000; 135(11).
- Clemente C, Elba S, Buongiorno G, Berloco P, Guerra V, A DL. Serum retinol and risk of hepatocellular carcinoma in patients with child-Pugh class A cirrhosis. Cancer Lett 2002; 178(2): 123 – 129.
- Newsome PN, Beldon I, Moussa Y, et al. Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. Aliment Pharmacol Ther 2000; 14(10): 1295 – 1301.
- Lotan R. Retinoids in cancer chemoprevention. FASEB J 1996; 10(9): 1031 – 1039.
- Kim DG, Jo BH, You KR, DS A. Apoptosis induced by retinoic acid in Hep 3B cells in vitro. Cancer Let. 1996; 107(1): 149 – 159.
- Nakamura N, Shidoji Y, Moriwaki H, Y M. Apoptosis in human hepatoma cell line induced by 4,5-didehydro geranylgeranoic acid (acyclic retinoid) via down-regulation of transforming growth factor-alpha. Biochem Biophys Res Commun 1996; 219(1): 100 – 104.
- Nakamura N, Shidoji Y, Yamada Y, Hatakeyama H, Moriwaki H, Y M. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 1995; 207(1): 382 – 388.
- Hsu SL, Lin HM, CK C. Suppression of the tumorigenicity of human hepatoma hep3B cells by long-term retinoic acid treatment. Cancer Lett 1996; 99(1): 79 – 85.
- Morré DM, Kloppel TM, Rosenthal AL, PC F. Chemoprevention of tumor development and metastasis of transplantable hepatocellular carcinomas in rats by vitamin A. J Nutr 1980; 110(8): 1629 – 1634.
- Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334(24): 1561 – 1567.
- Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, ON M. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998; 42(3): 442 – 447.
- Becker G, Allgaier HP, Olschewski M, Zähringer A, Blum HE, Group HS. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007; 45(1): 9 – 15.
- Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84(7): 886 –891.
- Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5(10): 835 – 844.
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378 – 390.
- Qian C, Drozdzik M, Caselmann WH, J P. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol 2000; 32(2): 344 – 351.
- Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356(9232): 802 – 7.
- Butterfi eld LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 2001; 166(8): 5300 – 5308.
- Meng WS, Butterfi eld LH, Ribas A, et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001; 61: 8782 – 6.
- Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100: 376 – 82.
